company background image
MSON

MisonixNasdaqGM:MSON Stock Report

Market Cap

US$441.6m

7D

-2.0%

1Y

122.5%

Updated

27 Oct, 2021

Data

Company Financials +
MSON fundamental analysis
Snowflake Score
Valuation1/6
Future Growth1/6
Past Performance0/6
Financial Health5/6
Dividends0/6

MSON Overview

Misonix, Inc., together with its subsidiaries, designs, develops, manufactures, and markets minimally invasive surgical ultrasonic medical devices in the United States and internationally.

Misonix Competitors

Stryker

NYSE:SYK

US$103.0b

Integra LifeSciences Holdings

NasdaqGS:IART

US$5.9b

Cutera

NasdaqGS:CUTR

US$745.9m

Apyx Medical

NasdaqGS:APYX

US$476.4m

Price History & Performance

Summary of all time highs, changes and price drops for Misonix
Historical stock prices
Current Share PriceUS$25.34
52 Week HighUS$11.04
52 Week LowUS$26.99
Beta1.35
1 Month Change-4.38%
3 Month Change6.29%
1 Year Change122.48%
3 Year Change52.65%
5 Year Change262.00%
Change since IPO1,167.00%

Recent News & Updates

May 13
We Think Misonix (NASDAQ:MSON) Has A Fair Chunk Of Debt

We Think Misonix (NASDAQ:MSON) Has A Fair Chunk Of Debt

Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...

Shareholder Returns

MSONUS Medical EquipmentUS Market
7D-2.0%2.0%0.9%
1Y122.5%24.4%33.4%

Return vs Industry: MSON exceeded the US Medical Equipment industry which returned 24.4% over the past year.

Return vs Market: MSON exceeded the US Market which returned 33.4% over the past year.

Price Volatility

Is MSON's price volatile compared to industry and market?
MSON volatility
MSON Beta1.35
Industry Beta0.88
Market Beta1

Stable Share Price: MSON is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 5% a week.

Volatility Over Time: MSON's weekly volatility (5%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
1959281Stavros Vizirgianakishttps://www.misonix.com

Misonix, Inc., together with its subsidiaries, designs, develops, manufactures, and markets minimally invasive surgical ultrasonic medical devices in the United States and internationally. The company’s products include BoneScalpel, an ultrasonic bone cutting and sculpting system for surgical procedures involving the precise cutting and sculpting of bone while sparing soft tissue; SonaStar, a surgical aspirator, which is used to emulsify and remove soft and hard tumors primarily in the neuro and general surgery field; and SonicOne, an ultrasonic cleansing and debridement system that provides tissue specific debridement and cleansing of wounds and burns for the removal of devitalized tissue and fibrin deposits while sparing viable cells. Its products are used in various clinical specialties, such as neurosurgery, orthopedic surgery, general surgery, plastic surgery, wound care, and maxillo-facial surgical applications.

Misonix Fundamentals Summary

How do Misonix's earnings and revenue compare to its market cap?
MSON fundamental statistics
Market CapUS$441.55m
Earnings (TTM)-US$14.47m
Revenue (TTM)US$74.02m

6.0x

P/S Ratio

-30.5x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
MSON income statement (TTM)
RevenueUS$74.02m
Cost of RevenueUS$21.39m
Gross ProfitUS$52.64m
ExpensesUS$67.11m
Earnings-US$14.47m

Last Reported Earnings

Jun 30, 2021

Next Earnings Date

n/a

Earnings per share (EPS)-0.83
Gross Margin71.11%
Net Profit Margin-19.55%
Debt/Equity Ratio33.9%

How did MSON perform over the long term?

See historical performance and comparison

Valuation

Is Misonix undervalued compared to its fair value and its price relative to the market?

3.27x

Price to Book (PB) ratio


Share Price vs. Fair Value

Below Fair Value: Insufficient data to calculate MSON's fair value to establish if it is undervalued.

Significantly Below Fair Value: Insufficient data to calculate MSON's fair value to establish if it is undervalued.


Price To Earnings Ratio

PE vs Industry: MSON is unprofitable, so we can't compare its PE Ratio to the US Medical Equipment industry average.

PE vs Market: MSON is unprofitable, so we can't compare its PE Ratio to the US market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate MSON's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: MSON is good value based on its PB Ratio (3.3x) compared to the US Medical Equipment industry average (4.3x).


Future Growth

How is Misonix forecast to perform in the next 1 to 3 years based on estimates from 3 analysts?

31.4%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: MSON is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: MSON is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: MSON is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: MSON's revenue (15.1% per year) is forecast to grow faster than the US market (9.9% per year).

High Growth Revenue: MSON's revenue (15.1% per year) is forecast to grow slower than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: Insufficient data to determine if MSON's Return on Equity is forecast to be high in 3 years time


Past Performance

How has Misonix performed over the past 5 years?

-43.1%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: MSON is currently unprofitable.

Growing Profit Margin: MSON is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: MSON is unprofitable, and losses have increased over the past 5 years at a rate of 43.1% per year.

Accelerating Growth: Unable to compare MSON's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: MSON is unprofitable, making it difficult to compare its past year earnings growth to the Medical Equipment industry (36.1%).


Return on Equity

High ROE: MSON has a negative Return on Equity (-10.71%), as it is currently unprofitable.


Financial Health

How is Misonix's financial position?


Financial Position Analysis

Short Term Liabilities: MSON's short term assets ($59.3M) exceed its short term liabilities ($22.7M).

Long Term Liabilities: MSON's short term assets ($59.3M) exceed its long term liabilities ($41.0M).


Debt to Equity History and Analysis

Debt Level: MSON's debt to equity ratio (33.9%) is considered satisfactory.

Reducing Debt: Insufficient data to determine if MSON's debt to equity ratio has reduced over the past 5 years.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: MSON has sufficient cash runway for more than 3 years based on its current free cash flow.

Forecast Cash Runway: MSON has sufficient cash runway for 2.6 years if free cash flow continues to reduce at historical rates of 54.1% each year.


Dividend

What is Misonix current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate MSON's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate MSON's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if MSON's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if MSON's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of MSON's dividend in 3 years as they are not forecast to pay a notable one for the US market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

3.8yrs

Average management tenure


CEO

Stavros Vizirgianakis (51 yo)

5.08yrs

Tenure

US$2,756,226

Compensation

Mr. Stavros George Vizirgianakis, B.Com., has been the Chief Executive Officer of Misonix, Inc. since December 19, 2016 and served as its President since December 19, 2016 until September 2019. Mr. Vizirgi...


CEO Compensation Analysis

Compensation vs Market: Stavros's total compensation ($USD2.76M) is above average for companies of similar size in the US market ($USD1.70M).

Compensation vs Earnings: Stavros's compensation has increased whilst the company is unprofitable.


Leadership Team

Experienced Management: MSON's management team is considered experienced (3.8 years average tenure).


Board Members

Experienced Board: MSON's board of directors are not considered experienced ( 2.1 years average tenure), which suggests a new board.


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.


Top Shareholders

Company Information

Misonix, Inc.'s employee growth, exchange listings and data sources


Key Information

  • Name: Misonix, Inc.
  • Ticker: MSON
  • Exchange: NasdaqGM
  • Founded: 1959
  • Industry: Health Care Equipment
  • Sector: Healthcare
  • Market Cap: US$441.551m
  • Shares outstanding: 17.43m
  • Website: https://www.misonix.com

Number of Employees


Location

  • Misonix, Inc.
  • 1938 New Highway
  • Farmingdale
  • New York
  • 11735
  • United States

Listings


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2021/10/27 22:59
End of Day Share Price2021/10/27 00:00
Earnings2021/06/30
Annual Earnings2021/06/30


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.